AXGN vs. EDAP, ZYXI, SMLR, ELMD, OM, FONR, VANI, CUTR, BLFS, and EPIX
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Edap Tms (EDAP), Zynex (ZYXI), Semler Scientific (SMLR), Electromed (ELMD), Outset Medical (OM), FONAR (FONR), Vivani Medical (VANI), Cutera (CUTR), BioLife Solutions (BLFS), and ESSA Pharma (EPIX).
Edap Tms (NASDAQ:EDAP) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.
Edap Tms presently has a consensus price target of $14.67, indicating a potential upside of 105.42%. AxoGen has a consensus price target of $10.67, indicating a potential upside of 84.23%. Given AxoGen's higher probable upside, analysts plainly believe Edap Tms is more favorable than AxoGen.
62.7% of Edap Tms shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 0.2% of Edap Tms shares are held by insiders. Comparatively, 7.2% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, AxoGen had 8 more articles in the media than Edap Tms. MarketBeat recorded 10 mentions for AxoGen and 2 mentions for Edap Tms. AxoGen's average media sentiment score of -0.13 beat Edap Tms' score of -0.23 indicating that Edap Tms is being referred to more favorably in the media.
Edap Tms has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.
AxoGen has higher revenue and earnings than Edap Tms. AxoGen is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.
AxoGen received 101 more outperform votes than Edap Tms when rated by MarketBeat users. Likewise, 72.59% of users gave AxoGen an outperform vote while only 62.77% of users gave Edap Tms an outperform vote.
AxoGen has a net margin of -12.99% compared to AxoGen's net margin of -35.03%. Edap Tms' return on equity of -21.96% beat AxoGen's return on equity.
Summary
AxoGen beats Edap Tms on 13 of the 17 factors compared between the two stocks.
Get AxoGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
